These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Tau acts as a mediator for Alzheimer's disease-related synaptic deficits. Liao D; Miller EC; Teravskis PJ Eur J Neurosci; 2014 Apr; 39(7):1202-13. PubMed ID: 24712999 [TBL] [Abstract][Full Text] [Related]
43. Reduction of amyloid beta by Aβ3-10-KLH vaccine also decreases tau pathology in 3×Tg-AD mice. Zhang HY; Zhu K; Meng Y; Ding L; Wang JC; Yin WC; Yan Y; Cao YP Brain Res Bull; 2018 Sep; 142():233-240. PubMed ID: 30077729 [TBL] [Abstract][Full Text] [Related]
44. Genipin Attenuates Tau Phosphorylation and Aβ Levels in Cellular Models of Alzheimer's Disease. Li M; Cai N; Gu L; Yao L; Bi D; Fang W; Lin Z; Wu Y; Xu H; Li H; Hu Z; Xu X Mol Neurobiol; 2021 Aug; 58(8):4134-4144. PubMed ID: 33948899 [TBL] [Abstract][Full Text] [Related]
45. Emerging beta-amyloid therapies for the treatment of Alzheimer's disease. Conway KA; Baxter EW; Felsenstein KM; Reitz AB Curr Pharm Des; 2003; 9(6):427-47. PubMed ID: 12570807 [TBL] [Abstract][Full Text] [Related]
46. Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease. Manczak M; Reddy PH Hum Mol Genet; 2012 Dec; 21(23):5131-46. PubMed ID: 22926141 [TBL] [Abstract][Full Text] [Related]
47. Role of tau protein in Alzheimer's disease: The prime pathological player. Muralidar S; Ambi SV; Sekaran S; Thirumalai D; Palaniappan B Int J Biol Macromol; 2020 Nov; 163():1599-1617. PubMed ID: 32784025 [TBL] [Abstract][Full Text] [Related]
48. Human tau increases amyloid β plaque size but not amyloid β-mediated synapse loss in a novel mouse model of Alzheimer's disease. Jackson RJ; Rudinskiy N; Herrmann AG; Croft S; Kim JM; Petrova V; Ramos-Rodriguez JJ; Pitstick R; Wegmann S; Garcia-Alloza M; Carlson GA; Hyman BT; Spires-Jones TL Eur J Neurosci; 2016 Dec; 44(12):3056-3066. PubMed ID: 27748574 [TBL] [Abstract][Full Text] [Related]
49. Status and future directions of clinical trials in Alzheimer's disease. Plascencia-Villa G; Perry G Int Rev Neurobiol; 2020; 154():3-50. PubMed ID: 32739008 [TBL] [Abstract][Full Text] [Related]
50. The past, present, and future of disease-modifying therapies for Alzheimer's disease. Suzuki K; Iwata A; Iwatsubo T Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(10):757-771. PubMed ID: 29225305 [TBL] [Abstract][Full Text] [Related]
51. The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer's disease. Jazvinšćak Jembrek M; Slade N; Hof PR; Šimić G Prog Neurobiol; 2018 Sep; 168():104-127. PubMed ID: 29733887 [TBL] [Abstract][Full Text] [Related]
52. Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice. Rasool S; Martinez-Coria H; Wu JW; LaFerla F; Glabe CG J Neurochem; 2013 Aug; 126(4):473-82. PubMed ID: 23672786 [TBL] [Abstract][Full Text] [Related]
53. Tau immunotherapies for Alzheimer's disease. Hoskin JL; Sabbagh MN; Al-Hasan Y; Decourt B Expert Opin Investig Drugs; 2019 Jun; 28(6):545-554. PubMed ID: 31094578 [TBL] [Abstract][Full Text] [Related]
54. Reducing Aβ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease. Kalra J; Khan A Eur J Pharmacol; 2015 Oct; 764():571-581. PubMed ID: 26209363 [TBL] [Abstract][Full Text] [Related]